PMID- 33253440
OWN - NLM
STAT- MEDLINE
DCOM- 20210903
LR  - 20210903
IS  - 1442-200X (Electronic)
IS  - 1328-8067 (Linking)
VI  - 63
IP  - 9
DP  - 2021 Sep
TI  - Decline of serum albumin precedes severe acute GVHD after haploidentical HSCT.
PG  - 1048-1054
LID - 10.1111/ped.14564 [doi]
AB  - BACKGROUND: Haploidentical hematopoietic stem cell transplantation (HSCT) is a 
      useful therapy for relapsed/refractory acute leukemia or lymphoma because of the 
      strong graft-vs-leukemia (GVL) effect. However, it is often accompanied by severe 
      acute graft-versus-host disease (aGVHD), which is the most serious complication 
      after haploidentical HSCT. Thus, it is important to control the severity of aGVHD 
      while maintaining the GVL effect. In our experience of pediatric haploidentical 
      HSCT, it takes several days for aGVHD to become severe after the appearance of 
      initial symptoms, mostly skin rashes. In this study, we aimed to identify useful 
      biomarkers at the onset of aGVHD that predict subsequent development of severe 
      aGVHD. METHODS: Forty-five consecutive children with relapsed/refractory acute 
      leukemia or lymphoma who developed aGVHD after haploidentical HSCT were enrolled. 
      We analyzed possible biomarkers from samples collected at the onset of acute 
      GVHD. RESULTS: Nineteen patients developed grade 1-2 aGVHD, and 26 patients 
      developed grade 3-4 aGVHD. There was no significant difference in patient 
      characteristics between the two groups. Transplant-related mortality occurred 
      only in the grade 3-4 aGVHD group (34.5%). Multivariate analysis revealed that 
      serum albumin was an independent biomarker for predicting the severity of aGVHD 
      (P = 0.009). The area under the receiver operating characteristic curve of serum 
      albumin was 0.864. CONCLUSIONS: The serum albumin level at the onset of aGvHD 
      could be a useful biomarker for the development of subsequent severe aGVHD in 
      pediatric patients after haploidentical HSCT.
CI  - (c) 2020 Japan Pediatric Society.
FAU - Takahashi, Nobuhisa
AU  - Takahashi N
AUID- ORCID: 0000-0003-0508-1906
AD  - Department of Pediatric Oncology, Fukushima Medical University Hospital, 
      Fukushima City, Japan.
FAU - Mochizuki, Kazuhiro
AU  - Mochizuki K
AD  - Department of Pediatric Oncology, Fukushima Medical University Hospital, 
      Fukushima City, Japan.
FAU - Sano, Hideki
AU  - Sano H
AD  - Department of Pediatric Oncology, Fukushima Medical University Hospital, 
      Fukushima City, Japan.
FAU - Kobayashi, Shogo
AU  - Kobayashi S
AUID- ORCID: 0000-0003-2305-942X
AD  - Department of Pediatric Oncology, Fukushima Medical University Hospital, 
      Fukushima City, Japan.
FAU - Ohara, Yoshihiro
AU  - Ohara Y
AD  - Department of Pediatric Oncology, Fukushima Medical University Hospital, 
      Fukushima City, Japan.
FAU - Ikeda, Kazuhiko
AU  - Ikeda K
AD  - Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical 
      University Hospital, Fukushima City, Japan.
FAU - Ohto, Hitoshi
AU  - Ohto H
AD  - Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical 
      University Hospital, Fukushima City, Japan.
FAU - Kikuta, Atsushi
AU  - Kikuta A
AD  - Department of Pediatric Oncology, Fukushima Medical University Hospital, 
      Fukushima City, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210714
PL  - Australia
TA  - Pediatr Int
JT  - Pediatrics international : official journal of the Japan Pediatric Society
JID - 100886002
RN  - 0 (Serum Albumin)
SB  - IM
MH  - Acute Disease
MH  - Child
MH  - *Graft vs Host Disease/diagnosis/etiology
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - *Leukemia
MH  - Serum Albumin
OTO - NOTNLM
OT  - acute GVHD
OT  - albumin
OT  - biomarker
OT  - children
OT  - haploidentical hematopoietic stem cell transplantation
EDAT- 2020/12/01 06:00
MHDA- 2021/09/04 06:00
CRDT- 2020/11/30 17:14
PHST- 2020/10/26 00:00 [revised]
PHST- 2020/04/15 00:00 [received]
PHST- 2020/11/25 00:00 [accepted]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/09/04 06:00 [medline]
PHST- 2020/11/30 17:14 [entrez]
AID - 10.1111/ped.14564 [doi]
PST - ppublish
SO  - Pediatr Int. 2021 Sep;63(9):1048-1054. doi: 10.1111/ped.14564. Epub 2021 Jul 14.